Literature DB >> 18362189

Antistreptococcal activity of AR-709 compared to that of other agents.

Kathy Smith1, Lois M Ednie, Peter C Appelbaum, Stephen Hawser, Sergio Lociuro.   

Abstract

Against 300 strains of pneumococci and 100 group A streptococci of differing beta-lactam, macrolide, and quinolone resistance phenotypes, AR-709 was very active, with all MICs being < or =2 microg/ml. Furthermore, AR-709 was active against strains that were both susceptible and resistant to trimethoprim-sulfamethoxazole.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18362189      PMCID： PMC2415763          DOI： 10.1128/AAC.01620-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada.

Authors:  J C De Azavedo; R H Yeung; D J Bast; C L Duncan; S B Borgia; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis.

Authors:  R Munoz; J M Musser; M Crain; D E Briles; A Marton; A J Parkinson; U Sorensen; A Tomasz
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

3.  In vitro activity of AR-709 against Streptococcus pneumoniae.

Authors:  W T M Jansen; A Verel; J Verhoef; D Milatovic
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

4.  Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.

Authors:  M R Jacobs; S Bajaksouzian; A Zilles; G Lin; G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 5.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

6.  Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents.

Authors:  G A Pankuch; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

7.  Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay area of northern California.

Authors:  M K York; L Gibbs; F Perdreau-Remington; G F Brooks
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

8.  Resistance of Streptococcus pyogenes to erythromycin and related antibiotics in Italy. The Italian Surveillance Group for Antimicrobial Resistance.

Authors:  G Cornaglia; M Ligozzi; A Mazzariol; L Masala; G Lo Cascio; G Orefici; R Fontana
Journal:  Clin Infect Dis       Date:  1998-08       Impact factor: 9.079

9.  In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae.

Authors:  G A Pankuch; S A Jueneman; T A Davies; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children.

Authors:  Michael E Pichichero; Janet R Casey
Journal:  JAMA       Date:  2007-10-17       Impact factor: 56.272
View more
  4 in total

1.  Structure-activity relationship for enantiomers of potent inhibitors of B. anthracis dihydrofolate reductase.

Authors:  Christina R Bourne; Nancy Wakeham; Baskar Nammalwar; Vladimir Tseitin; Philip C Bourne; Esther W Barrow; Shankari Mylvaganam; Kal Ramnarayan; Richard A Bunce; K Darrell Berlin; William W Barrow
Journal:  Biochim Biophys Acta       Date:  2012-09-20

2.  Synthesis and biological activity of substituted 2,4-diaminopyrimidines that inhibit Bacillus anthracis.

Authors:  Baskar Nammalwar; Richard A Bunce; K Darrell Berlin; Christina R Bourne; Philip C Bourne; Esther W Barrow; William W Barrow
Journal:  Eur J Med Chem       Date:  2012-05-22       Impact factor: 6.514

3.  Modified 2,4-diaminopyrimidine-based dihydrofolate reductase inhibitors as potential drug scaffolds against Bacillus anthracis.

Authors:  Baskar Nammalwar; Christina R Bourne; Nancy Wakeham; Philip C Bourne; Esther W Barrow; N Prasad Muddala; Richard A Bunce; K Darrell Berlin; William W Barrow
Journal:  Bioorg Med Chem       Date:  2014-11-11       Impact factor: 3.641

4.  A microdose study of ¹⁴C-AR-709 in healthy men: pharmacokinetics, absolute bioavailability and concentrations in key compartments of the lung.

Authors:  G Lappin; M J Boyce; T Matzow; S Lociuro; M Seymour; S J Warrington
Journal:  Eur J Clin Pharmacol       Date:  2013-06-06       Impact factor: 2.953
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.